This is a narrative review assessing MSN technology for cancer therapy without reporting original clinical trial data, efficacy comparisons, or quantified outcomes; it raises mechanistic and design questions rather than answering them with empirical evidence.
This is a narrative review discussing CRISPR-Cas potential in oncology without reporting empirical data, clinical outcomes, or trial results; it presents conceptual possibilities and technical developments rather than evidence of efficacy.
This is a narrative review synthesizing preclinical mechanistic evidence and proposing a theoretical framework; it does not report primary experimental data, clinical outcomes, or comparative efficacy studies.